City File: Rise in sight

M L Laboratories should receive final official approval for its Dextrin 20 kidney dialysis drug by the end of the year. The shares, which have been as high as 963p but have fallen to below 750p, are expected to rise in anticipation of an announcement. M L says there are 380,000 dialysis patients worldwide - a figure expected to soar with the opening up of Eastern Europe, where renal patients are rarely treated. Dextrin 20 is said to be a cleaner, safer and easier solution to the present, far from perfect, dialysis treatment. M L, if all goes to plan, could just be the next Glaxo.